Sally C. Pipes

Commentary

America Doesn’t Have Enough Doctors. Medicare Is Making That Worse.

The United States is facing a shortage of 37,000 physicians, according to the latest research from the Association of American Medical Colleges. That deficit will more than double to 86,000 doctors by 2036. Medicare’s chronically low reimbursement rates deserve at least part of the blame. According to the American Medical ...
Commentary

How Price Controls Make a Healthy Drug Market Sick

The unspoken assumption behind the prescription drug price controls at the heart of the Democrats’ August 2022 Inflation Reduction Act (IRA) is that the pharmaceutical market is broken. According to this view, drugmakers have the power to charge whatever they want. Only a sweeping system of government price-setting can put ...
Commentary

Medicare Turns 60 This Month: It’s Time for an Intervention

On July 30, Medicare will mark its 60th birthday. Like many 60-year-olds, it’s in the throes of a midlife crisis. But unlike a harmless convertible purchase or spontaneous trip to Paris, this one midlife crisis threatens the nation’s fiscal health — and the well-being of future retirees. Read the entire ...
Commentary

Thank Obamacare for America’s insurance fraud boom

The number of Americans enrolled in marketplace plans either fraudulently or improperly reached 6.4 million in 2025 — an increase of more than one-quarter, according to an analysis published last month by the Paragon Health Institute. All of this wrongdoing will cost American taxpayers an estimated $27 billion this year. ...
Commentary

Feds right to curtail California’s Medicaid scam

On Independence Day, President Trump signed the One Big Beautiful Bill Act, which is projected to reduce enrollment in Medicaid programs throughout the country, including Medi-Cal in California. But Californians should cheer, not jeer, these coverage “losses.” The law will primarily disenroll people who should have never been covered by ...
Commentary

Let’s talk about medical debt

A federal judge this month tossed out a Biden-era rule that would have wiped medical debt from consumers’ credit reports. The decision is a victory for borrowers and lenders alike. The now-defunct rule could have ended up hurting the very low-income individuals it was meant to help. Read the entire ...
Commentary

Trump Must Shut Down Counterfeit Weight-Loss Drugs

Americans looking to lose weight are increasingly turning to the internet. And they’re being duped. Telehealth startups and fly-by-night pharmacies are peddling what look like cheap, convenient versions of blockbuster drugs like Ozempic and Wegovy. But many of these offerings are neither authentic nor safe. They’re “compounded” copies — knockoffs ...
Commentary

The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One

Buried within the One Big Beautiful Bill Act, which President Donald Trump signed into law July 4, is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases. That provision is the Orphan Cures Act, which exempts certain drugs that treat ...
Commentary

One Big Beautiful Bill: A Fiscal Lifeline for Medicaid, Taxpayers

The “One Big Beautiful Bill” Act (OBBBA) signed into law by President Donald Trump on July 4 is set to help pull America’s healthcare system back from the brink of fiscal disaster. Read the entire op-ed here.
Commentary

The Culprit Impeding Drug Competition Is Not Who The Feds Expected

The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry. The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists ...
Commentary

America Doesn’t Have Enough Doctors. Medicare Is Making That Worse.

The United States is facing a shortage of 37,000 physicians, according to the latest research from the Association of American Medical Colleges. That deficit will more than double to 86,000 doctors by 2036. Medicare’s chronically low reimbursement rates deserve at least part of the blame. According to the American Medical ...
Commentary

How Price Controls Make a Healthy Drug Market Sick

The unspoken assumption behind the prescription drug price controls at the heart of the Democrats’ August 2022 Inflation Reduction Act (IRA) is that the pharmaceutical market is broken. According to this view, drugmakers have the power to charge whatever they want. Only a sweeping system of government price-setting can put ...
Commentary

Medicare Turns 60 This Month: It’s Time for an Intervention

On July 30, Medicare will mark its 60th birthday. Like many 60-year-olds, it’s in the throes of a midlife crisis. But unlike a harmless convertible purchase or spontaneous trip to Paris, this one midlife crisis threatens the nation’s fiscal health — and the well-being of future retirees. Read the entire ...
Commentary

Thank Obamacare for America’s insurance fraud boom

The number of Americans enrolled in marketplace plans either fraudulently or improperly reached 6.4 million in 2025 — an increase of more than one-quarter, according to an analysis published last month by the Paragon Health Institute. All of this wrongdoing will cost American taxpayers an estimated $27 billion this year. ...
Commentary

Feds right to curtail California’s Medicaid scam

On Independence Day, President Trump signed the One Big Beautiful Bill Act, which is projected to reduce enrollment in Medicaid programs throughout the country, including Medi-Cal in California. But Californians should cheer, not jeer, these coverage “losses.” The law will primarily disenroll people who should have never been covered by ...
Commentary

Let’s talk about medical debt

A federal judge this month tossed out a Biden-era rule that would have wiped medical debt from consumers’ credit reports. The decision is a victory for borrowers and lenders alike. The now-defunct rule could have ended up hurting the very low-income individuals it was meant to help. Read the entire ...
Commentary

Trump Must Shut Down Counterfeit Weight-Loss Drugs

Americans looking to lose weight are increasingly turning to the internet. And they’re being duped. Telehealth startups and fly-by-night pharmacies are peddling what look like cheap, convenient versions of blockbuster drugs like Ozempic and Wegovy. But many of these offerings are neither authentic nor safe. They’re “compounded” copies — knockoffs ...
Commentary

The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One

Buried within the One Big Beautiful Bill Act, which President Donald Trump signed into law July 4, is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases. That provision is the Orphan Cures Act, which exempts certain drugs that treat ...
Commentary

One Big Beautiful Bill: A Fiscal Lifeline for Medicaid, Taxpayers

The “One Big Beautiful Bill” Act (OBBBA) signed into law by President Donald Trump on July 4 is set to help pull America’s healthcare system back from the brink of fiscal disaster. Read the entire op-ed here.
Commentary

The Culprit Impeding Drug Competition Is Not Who The Feds Expected

The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry. The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists ...
Scroll to Top